Maven Securities LTD Affimed N.V. Transaction History

Maven Securities LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $364,537 - $494,165	-65,801 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$7.78 - $11.4 $1.91 Million - $2.8 Million	-245,328 Reduced 78.85%	65,801 $559,000
Q1 2021 May 17, 2021	BUY	$5.12 - $8.48 $837,616 - $1.39 Million	163,597 Added 110.89%	311,129 $2.46 Million
Q4 2020 Feb 12, 2021	BUY	$3.16 - $7.03 $466,201 - $1.04 Million	147,532 New	147,532 $884,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $491M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.